4//SEC Filing
Haas Jason 4
Accession 0000950170-24-040289
CIK 0001556263other
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 4:54 PM ET
Size
12.2 KB
Accession
0000950170-24-040289
Insider Transaction Report
Form 4
Haas Jason
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-03-31+2,000→ 15,951 total - Exercise/Conversion
Restricted Stock Units
2024-03-31−13,333→ 26,667 total→ Common Stock (13,333 underlying) - Exercise/Conversion
Restricted Stock Units
2024-03-31−2,000→ 4,000 total→ Common Stock (2,000 underlying) - Exercise/Conversion
Common Stock
2024-03-31+13,333→ 29,284 total - Tax Payment
Common Stock
2024-04-01$5.12/sh−4,732$24,228→ 24,552 total
Footnotes (5)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Represents shares used to cover tax withholding upon the release of restricted stock units.
- [F3]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F4]Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.
- [F5]Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024.
Documents
Issuer
Syros Pharmaceuticals, Inc.
CIK 0001556263
Entity typeother
Related Parties
1- filerCIK 0001883821
Filing Metadata
- Form type
- 4
- Filed
- Apr 1, 8:00 PM ET
- Accepted
- Apr 2, 4:54 PM ET
- Size
- 12.2 KB